eligibility_summary
Eligibility: Adults ≥18 with confirmed BV‑MCL, ECOG 0–2, life expectancy ≥3 months, measurable disease, no prior PI3K/BCL‑2 inhibitors, adequate marrow/organ labs, off other trials ≥4 weeks, negative pregnancy test/contraception, consent. Exclude CNS disease, active infection, pregnancy/lactation, drug allergy, other invasive cancer <3 years, oral‑intake limits, uncontrolled CV, pulmonary, hepatic (incl active HBV/HCV), renal dialysis, diabetes, effusions/proteinuria, immunodeficiency/HIV/transplant, severe/uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06324994 tests a chemo‑free triple regimen in relapsed/refractory blastoid mantle cell lymphoma: linperlisib (oral small‑molecule, selective PI3Kδ inhibitor), obinutuzumab (IV type II glycoengineered anti‑CD20 monoclonal antibody), and venetoclax (oral small‑molecule BH3‑mimetic BCL‑2 inhibitor). Targets/mechanisms: linperlisib blocks PI3Kδ within B‑cell receptor signaling to suppress PI3K/AKT/mTOR–driven survival and proliferation, venetoclax inhibits BCL‑2 to restore mitochondrial apoptosis, obinutuzumab binds CD20 on malignant B cells, driving direct cell death and enhanced ADCC/ADCP (with limited CDC). Overall, the combo targets CD20+ mantle cell lymphoma cells and the PI3K/AKT/mTOR and BCL‑2 anti‑apoptotic pathways.